DSpace

DSpace at RU >    University Library >    Academic bibliography >

SFX Query

Files in This Item:

File Description SizeFormat
publisher's version332.82 kBAdobe PDFUnder Embargo

Title: Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
Author(s): Martino, R.
Iacobelli, S.
Brand, R.
Jansen, T.
Biezen, A. van (298203944)
Finke, J. (298207761)
Bacigalupo, A.
Beelen, D.
Reiffers, J. (169205479)
Devergie, A. (298203898)
Alessandrino, E.
Mufti, G.J.
Barge, R.M. (072967021)
Sierra, J. (298206595)
Ruutu, T. (298204436)
Boogaerts, M.
Falda, M.
Jouet, J.P.
Niederwieser, D.
Witte, T.J.M. de (069336474)
Publication year: 2006
Document type: Article / Letter to editor
Journal: Blood
ISSN: 0006-4971
Volume: vol. 108
Issue: iss. 3
Start page: p. 836
End page: p. 846
Abstract: In this multicenter retrospective study, the outcomes of 836 patients with myelodysplastic syndrome (MDS) who underwent transplantation with a human leukocyte antigen (HLA)-identical sibling donor were analyzed according to 2 types of conditioning: reduced-intensity conditioning (RIC) in 215 patients, and standard myeloablative (or high-dose) conditioning (SMC) in 621 patients. In multivariate analysis, the 3-year relapse rate was significantly increased after RIC (hazard ratio [HR], 1.64; 95% confidence interval [95% CI], 1.2-2.2; P = .001), but the 3-year nonrelapse mortality (NRM) rate was decreased in the RIC group (HR, 0.61; 95% CI, 0.41-0.91; P = .015). The 3-year probabilities of progression-free and overall survivals were similar in both groups (39% after SMC vs 33% in RIC; multivariate P = .9; and 45% vs 41%, respectively; P = .8). In conclusion, the lower 3-year NRM after RIC is encouraging, since these patients were older (age > 50 years in 73% RIC vs 28% in SMC, P < .001) and had more adverse pretransplantation variables. However, based on the higher risk of relapse, patients with no contraindications for SMC should not receive RIC outside of prospective randomized trials, which are needed to establish the position of RIC-based transplantation in the treatment of patients with MDS.
Subject: UMCN 1.2: Molecular diagnosis, prognosis and monitoring
UMCN 1.4: Immunotherapy, gene therapy and transplantation
Organization: UMCN Extern
Radboud University Nijmegen Medical Centre
CHL
Appears in Collections:Academic bibliography

Please use this identifier to cite or link to this item: http://hdl.handle.net/2066/50336

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

  DSpace Software Copyright © 2002-2011  Duraspace - Feedback